Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

abstract：:Involvement of the gastrointestinal (GI) tract by multiple myeloma (MM) is extremely rare. The small intestine and stomach are the most frequent sites of spread. We report 1 case of a 61-year-old woman who presented with clinical and radiographic features of an acute large bowel pseudo-obstruction. An abdominal comput...

journal_title：Leukemia & lymphoma

authors： Venizelos I,Theodoridou S,Vakalopoulou S,Perifanis V,Vyzantiadis T,Garipidou V

更新日期：2004-09-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) is a severe complication in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. Central nervous system (CNS) involvement of PTLD is a very rare event in patients with HSCT. As no established standard therapy i...

journal_title：Leukemia & lymphoma

authors： Czyzewski K,Styczynski J,Krenska A,Debski R,Zajac-Spychala O,Wachowiak J,Wysocki M

更新日期：2013-03-01 00:00:00

abstract：:Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) have been implicated in the pathogenesis of adult T-cell leukemia/lymphoma, but their effects on T-cells have not been well studied. Here we analyzed the functions of PTHrP and MIP-1α on T-cell growth and death both in vitro an...

journal_title：Leukemia & lymphoma

authors： Shu ST,Dirksen WP,Lanigan LG,Martin CK,Thudi NK,Werbeck JL,Fernandez SA,Hildreth BE 3rd,Rosol TJ

更新日期：2012-04-01 00:00:00

abstract：:Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections...

journal_title：Leukemia & lymphoma

authors： Tallman MS,Polliack A

更新日期：2009-10-01 00:00:00

abstract：:It has recently been postulated that the absence of a single tumor suppressor gene (TSG) allele can provide a selective advantage for an emerging tumor cell. We have characterized the precise extension of the deletion on der(9) in 20 chronic myeloid leukemia (CML) cases using FISH analysis with an appropriate set of B...

journal_title：Leukemia & lymphoma

authors： Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Liso A,Pannunzio A,Pastore D,Mestice A,Greco G,Liso V,Rocchi M

更新日期：2004-04-01 00:00:00

abstract：:Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

journal_title：Leukemia & lymphoma

authors： Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

更新日期：2006-06-01 00:00:00

abstract：:Mutations of the TP53 tumor suppressor gene, contributing to the development and progression of a wide variety of human malignancies, are found in some of the patients with myelodysplastic syndromes (MDS). Previous reports revealed that TP53 mutations were found in 0-25% of patients with MDS and are closely associated...

journal_title：Leukemia & lymphoma

authors： Misawa S,Horiike S

更新日期：1996-11-01 00:00:00

abstract：:This study reports an autopsy case of a 53 year-old male with rapidly progressive extra-nodal NK/T-cell lymphoma accompanied with unusual clinical and pathologic features. He was initially presented with localized swelling and tenderness in the right lower extremity and the biopsy from the calf muscle was interpreted ...

journal_title：Leukemia & lymphoma

authors： Min HS,Hyun CL,Paik JH,Jeon YK,Choi G,Park SH,Seo JW,Kim CW

更新日期：2006-02-01 00:00:00

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and fatal disease of early childhood characterized by a non-malignant accumulation of activated T lymphocytes and histiocytes in the reticuloendothelial system. Moreover, immune system derangement, with prominent hypercytokinemia and low or absent cytotoxic T...

journal_title：Leukemia & lymphoma

authors： Fadeel B,Orrenius S,Henter JI

更新日期：2001-06-01 00:00:00

abstract：:Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediat...

journal_title：Leukemia & lymphoma

authors： Gupta V,Griesshammer M,Martino B,Foltz L,Tavares R,Al-Ali HK,Giraldo P,Guglielmelli P,Lomaia E,Bouard C,Paley C,Tiwari R,Zor E,Raanani P

更新日期：2020-11-19 00:00:00

abstract：:Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

journal_title：Leukemia & lymphoma

authors： Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

更新日期：2005-12-01 00:00:00

abstract：:Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

journal_title：Leukemia & lymphoma

authors： Gifford G,Stevenson W,Best G

更新日期：2020-12-01 00:00:00

abstract：:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1993-01-01 00:00:00

abstract：:Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) me...

journal_title：Leukemia & lymphoma

authors： Jardin F,Delfau-Larue MH,Molina TJ,Copie-Bergman C,Brière J,Petrella T,Canioni D,Fabiani B,Jais JP,Figeac M,Leroy K,Mareschal S,Salles GA,Coiffier B,Delarue R,Peyrade F,Bosly A,André M,Ketterer N,Haioun C,Tilly H

更新日期：2013-09-01 00:00:00

abstract：:A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...

journal_title：Leukemia & lymphoma

authors： Quitt M,Bazac I,Gross B,Aghai E

更新日期：1994-11-01 00:00:00

abstract：:Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

journal_title：Leukemia & lymphoma

authors： Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

更新日期：2005-12-01 00:00:00

abstract：:Constitutively activated STAT3 is correlated with more advanced clinical stage and overall poor survival of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate STAT3 and Ki67 tumor cell expression, inflammatory cell infiltration, microvascular density in DLBCL bioptic specimens. RNA-scope show...

journal_title：Leukemia & lymphoma

authors： Tamma R,Ingravallo G,Gaudio F,Annese T,Albano F,Ruggieri S,Dicataldo M,Maiorano E,Specchia G,Ribatti D

更新日期：2020-03-01 00:00:00

abstract：:We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

journal_title：Leukemia & lymphoma

authors： Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

更新日期：2016-09-01 00:00:00

abstract：:Serum amino-terminal pro-brain natriuretic peptide (NT-proBNP) is considered as a prognostic marker in patients with severe sepsis or septic shock, but no data are available on NT-proBNP kinetics in hematological patients with neutropenic fever. Altogether 70 hematological patients with neutropenic fever were included...

journal_title：Leukemia & lymphoma

authors： Hämäläinen S,Juutilainen A,Kuittinen T,Nousiainen T,Matinlauri I,Pulkki K,Koivula I,Jantunen E

更新日期：2010-06-01 00:00:00

abstract：:Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets. It is unclear whether the clinical respons...

journal_title：Leukemia & lymphoma

authors： Strupp C,Germing U,Aivado M,Kündgen A,Fenk R,Hünerlitürkoglu A,Kobbe G,Haas R,Gattermann N

更新日期：2005-07-01 00:00:00

abstract：:In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one pat...

journal_title：Leukemia & lymphoma

authors： Rodriguez V,Anderson PM,Litzow MR,Erlandson L,Trotz BA,Arndt CA,Khan SP,Wiseman GA

更新日期：2006-08-01 00:00:00

abstract：:In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...

journal_title：Leukemia & lymphoma

authors： Gisslinger H,Kurzrock R,Wetzler M,Tucker S,Kantarjian H,Robertson B,Talpaz M

更新日期：1997-03-01 00:00:00

abstract：:The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

journal_title：Leukemia & lymphoma

authors： Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

更新日期：1995-03-01 00:00:00

abstract：:The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ib...

journal_title：Leukemia & lymphoma

authors： Chai KL,Rowan G,Seymour JF,Burbury K,Carney D,Tam CS

更新日期：2017-12-01 00:00:00

abstract：:There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

journal_title：Leukemia & lymphoma

authors： Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

更新日期：2019-08-01 00:00:00

abstract：:Chronic lymphocytic leukemia cell (CLL) usually (95%) express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells. However, among B CLL, 7 to 20% do not express CD5. The significance of the lack of CD5 expression remains unclear. We reviewed 42 consecutive CD5- B CLL seen in three...

journal_title：Leukemia & lymphoma

authors： Cartron G,Linassier C,Bremond JL,Desablens B,Georget MT,Fimbel B,Luthier F,Dutel JL,Lamagnere JP,Colombat P

更新日期：1998-09-01 00:00:00

abstract：:Interleukin-4 (IL-4), also known as B-cell stimulatory factor-1 (BSF-1), was initially identified as a T-cell product that mediates anti-IgM-induced DNA synthesis in B-lymphocytes. Various aspects of this highly pleiotropic cytokine have been described, including those on hematopoietic progenitor cells. However, the r...

journal_title：Leukemia & lymphoma

authors： Sawada K,Sato N,Koike T

更新日期：1995-09-01 00:00:00

abstract：:Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

journal_title：Leukemia & lymphoma

authors： Arora B,Mesa R,Tefferi A

更新日期：2004-12-01 00:00:00

abstract：:Although current immunochemotherapy has increased the therapeutic efficacy in diffuse large B-cell lymphoma (DLBCL), there are still some patients who present unfavorable outcomes. Novel effective treatment strategies are needed to improve the prognosis of DLBCL. In this review, we discussed the functional mechanisms ...

journal_title：Leukemia & lymphoma

authors： Wang M,Fang X,Wang X

更新日期：2020-04-01 00:00:00